COVA Acquisition Corp Ordinary Shares - Class A COVA 深 滬
已收盤 12-20 16:00:00 美东时间
10.55
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 10.55
- 總市值 3.96亿
- 52周最高 11.32
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 9.40
- 委 比 0.00%
- 總股本 3750.00万
- 歷史最高 11.32
- 量 比 0
- 振 幅 0.00%
- 歷史最低 9.40
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多礼来GIP/GLP-1受体激动剂替尔泊肽在大型头对头研究中展现出心血管保护作用
摘要：进一步证实其可为2型糖尿病合并心血管疾病患者带来获益 SURPASS-CVOT研究达到主要终点，替尔泊肽组与度拉糖肽组相比在MACE-3事件发生率方面显示...
08-01 18:13
Biomea Fusion Announced The Presentation Of New Preclinical And Clinical Data For Icovamenib At The Scientific Sessions Of The American Diabetes Association
In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass, outperforming the
06-23 19:11
Biomea Fusion Presents Updated Preliminary Clinical Data From Ongoing Phase I COVALENT-103 Trial Of BMF-500 In Adults With R/R Acute Leukemia, At EHA 2025 Congress
Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced updated preliminary clinical data from the ongoing Phase I COVALENT-103 trial of
06-13 18:47
Biomea Fusion's BMF-500 Selected For Poster Presentation At EHA 2025 Highlighting Phase I Data In Relapsed/Refractory Acute Leukemia
Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the Phase I COVALENT-103 trial of BMF-500 in adults with acute
05-15 04:33
又一家药企被要求退款，三叶草生物与Gavi纠纷的双重冲击与行业影响
撰文：Pharmadeep编辑：活力哈哈 2025年3月21日，全球疫苗免疫联盟（Gavi）以书面通知单方面终止与三叶草生物（2197.HK）的新冠疫苗预购协议...
03-27 07:31
Biomea Fusion Advances Diabetes Treatment with Positive Study Results
The latest announcement is out from Biomea Fusion ( ($BMEA) ). Biomea Fusion an...
2024-12-21 04:27
Biophytis Announces Promising COVID-19 Study Results
Biophytis SA (FR:ALBPS) has released an update. Biophytis SA has reported posit...
2024-07-01 13:40
Why Biomea Fusion (BMEA) Stock Is Down 60%
Biomea Fusion shares are trading lower by 62.7% during Friday's session. The company received notice from the FDA that Its trials of BMF-219 have been placed on clinical hold.
2024-06-08 00:04
Biomea Fusion cut at Barclays following clinical hold
Barclays has downgraded Biomea Fusion (NASDAQ:BMEA) to equal weight from overweight citing the June 6 announcement that the U.S. FDA placed a full clinical hold on phase 1/2 trials for BMF-219 for typ...
2024-06-07 20:59
